First COVID-19 Vaccine by Russia
Human Trials Of Russia’s COVID-19 Vaccine Completed Successfully
After Russia’s COVID-19 vaccine candidate showed results that prove the medication’s effectiveness, it becomes the first nation to complete human clinical trials of coronavirus vaccine.
On Sunday, the head of the Center for Clinical Research on Medications at Sechenov University, Chief researcher Elena Smolyarchuk the told Russian news agency that at the university, the human trials for the coronavirus vaccine have been completed and they will be discharged soon.
According to the report, Smolyarchuk was quoted as, “The vaccine has been proved to be safe and the research has been completed. On the following days, June 15 and June 20, the volunteers will be discharged.”
However, further details on this vaccine entering the commercial production stage are not provided yet.
Gamaleya National Research Center for Epidemiology and Microbiology developed two forms of a potential COVID-19 and on June 18, they were allowed for clinical trials in Russia.
The first vaccine was carried out at the Burdenko Military Hospital in the form of a solution for intramuscular administration. A group of 18 volunteers was involved in the first stage of research on the vaccine at Sechenov University.
The second vaccine was carried out at Sechenov First Moscow State Medical University in the form of a powder for the preparation of a solution for intramuscular administration. Around 20 volunteers were involved in this second group.
For 28 days, all volunteers were expected to remain in isolation in a hospital after vaccination.
Earlier, a group of volunteers in Russia showed that they were developing immunity to the coronavirus according to the results of the coronavirus vaccine tests performed on them.
According to an earlier statement from the Russian Defense Ministry, “Volunteers of the first and second groups were seen to develop an immune response after injections of the vaccine against the coronavirus according to the data obtained by the Gamalei National Research Center for Epidemiology and Microbiology.”
However, the Russian coronavirus vaccine study is listed as a phase 1 trial according to the draft landscape of COVID-19 candidate vaccines prepared by the World Health Organization (WHO). According to WHO data, Oxford/AstraZeneca’s ChAdOx1-S and Sinovac’s vaccine based on inactivated COVID-19 particles are the only candidates to reach phase 3 trials as of July 7.